DMTKQ — DermTech Income Statement
0.000.00%
- $0.00m
- -$38.93m
- $15.30m
Annual income statement for DermTech, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 March 31st | R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 5.88 | 11.8 | 14.5 | 15.3 |
Cost of Revenue | |||||
Gross Profit | — | -0.096 | 1.27 | 0.647 | 0.276 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 1.98 | 41.2 | 89.2 | 133 | 119 |
Operating Profit | -1.98 | -35.3 | -77.4 | -118 | -104 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 0.944 | -36.5 | -78.3 | -117 | -101 |
Net Income After Taxes | 0.944 | -36.5 | -78.3 | -117 | -101 |
Net Income Before Extraordinary Items | |||||
Net Income | 0.944 | -36.5 | -78.3 | -117 | -101 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 0.743 | -36.5 | -78.3 | -117 | -101 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.145 | -2.15 | -2.71 | -3.89 | -3.09 |